Biomerica, Inc.

Equities

BMRA

US09061H3075

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.3569 ^USD	-2.75%		-18.14%	-71.45%

Jul. 01	Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers	CI
Jun. 28	Biomerica, Inc. Announces Resignation of Jack Kenny as Board of Directors and All Committees Thereof and as the Chairman of the Board	CI

Biomerica, Inc. Reports Earnings Results for the Second Quarter Ended November 30, 2020

January 14, 2021 at 04:16 pm EST

Biomerica, Inc. announced earnings results for the second quarter ended November 30, 2020. For the second quarter, the company announced sales was USD 1.372 million compared to USD 1.596 million a year ago. Operating loss was USD 1.479 million compared to USD 489,743 a year ago. Net loss was USD 1.485 million compared to USD 485,260 a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.05 a year ago. For the half year, sales was USD 2.516 million compared to USD 2.790 million a year ago. Operating loss was USD 3.136 million compared to USD 1.000 million a year ago. Net loss was USD 3.134 million compared to USD 991,556 a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.1 a year ago.

Latest news about Biomerica, Inc.

Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers	Jul. 01	CI
Biomerica, Inc. Announces Resignation of Jack Kenny as Board of Directors and All Committees Thereof and as the Chairman of the Board	Jun. 28	CI
Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024	May. 13	CI
Biomerica Enters Distribution Deal to Provide Home Screening Tests in UAE	Apr. 29	MT
Biomerica and UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement	Apr. 29	CI
Biomerica Provides Update on inFoods IBS Expansion	Apr. 15	CI
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 12	CI
Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board	Feb. 21	CI
Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors	Jan. 23	CI
Biomerica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 16	CI
Top Premarket Decliners	Dec. 19	MT
Biomerica Shares Rise After FDA 510(k) Clearance for H Pylori Bacteria Test	Dec. 18	DJ
Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria	Dec. 18	CI
Biomerica, Inc. Expands in Foods IBS Reach with Addition of Several New GI Groups	Nov. 08	CI
Biomerica, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-12	CI
Biomerica Says Dubai Approves Insurance Reimbursement for Colorectal Disease Screening Test	23-09-26	MT
Jack Kenny Joins Biomerica?S Board of Directors	23-08-28	CI
Biomerica, Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	23-08-25	CI
Biomerica's Colorectal Disease Screening Test to be Available in CVS Stores in September	23-08-03	MT
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Growth Index	23-06-23	CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Growth Index	23-06-23	CI
Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients	23-06-21	CI
Certain Stock Options of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023.	23-05-31	CI

Chart Biomerica, Inc.

Duration

Period

More charts

Company Profile

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physiciansâ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Companyâs two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIOMERICA, INC.	-71.45%	6M
ABBOTT LABORATORIES	-5.31%	181B
MEDTRONIC PLC	-5.38%	99.95B
BECTON, DICKINSON AND COMPANY	-6.04%	66.21B
HOYA CORPORATION	+16.45%	45.4B
DEXCOM, INC.	-8.08%	45.36B
CENCORA, INC.	+8.38%	43.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+12.06%	29.03B
TERUMO CORPORATION	+17.98%	25.64B
WEST PHARMACEUTICAL SERVICES, INC.	-8.28%	23.53B

Other Medical Equipment, Supplies & Distribution